Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 3 , Pages 375-388 , June 2009

Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus

References 

  1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–1431
  2. Carr ME. Diabetes mellitus: a hypercoagulable state. Journal of Diabetes and its Complications. 2001;15:44–54
  3. Laakso MLS. Epidemiology of macrovascular disease in diabetes. Diabetes Review. 1997;5:294–315
  4. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous coronary angioplasty. Circulation. 1995;91:979–989
  5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (Clinical Research Ed.). 2002;324:71–86
  6. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type-2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The New England Journal of Medicine. 1998;339:229–234
  7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  8. Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: current concepts. The American Journal of Medicine. 2004;116(Suppl. 5A):11S–22S
  9. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26:2181–2188
  10. Vinik AI, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24:1476–1485
  11. Ferroni P, Basili S, Falco A, et al. Platelet activation in type 2 diabetes mellitus. Journal of Thrombosis and Haemostasis. 2004;2:1282–1291
  12. Angiolillo DJ, Bernardo E, Sabaté M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. Journal of the American College of Cardiology. 2007;50:1541–1547
  13. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54:2430–2435
  14. Angiolillo DJ, Bernardo E, Ramírez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. Journal of the American College of Cardiology. 2006;48:298–304
  15. Watala C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Current Pharmaceutical Design. 2005;11:2331–2365
  16. Davì G, Gresele P, Violi F, et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation. 1997;96:69–75
  17. Davì G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99:224–229
  18. Davì G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. The New England Journal of Medicine. 1990;322:1769–1774
  19. Gresele P, Guglielmini G, De Angelis M, et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. Journal of the American College of Cardiology. 2003;41:1013–1020
  20. Assert R, Scherk G, Bumbure A, et al. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia. 2001;44:188–195
  21. Li Y, Woo W, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. American Journal of Physiology. Heart and Circulatory Physiology. 2001;280:H1480–H1489
  22. Vallés J, Santos MT, Aznar J, et al. Modulatory effect of erythrocytes on the platelet reactivity to collagen in IDDM patients. Diabetes. 1997;46:1047–1053
  23. Kobayashi K, Watanabe J, Umeda F, et al. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocrine Journal. 1995;42:461–465
  24. Millican SA, Schultz D, Bagga M, et al. Glucose-modified low density lipoprotein enhances human monocyte chemotaxis. Free Radical Research. 1998;28:533–542
  25. Ferretti G, Rabini RA, Bacchetti T, et al. Glycated low density lipoproteins modify platelet properties: a compositional and functional study. The Journal of Clinical Endocrinology and Metabolism. 2002;87:2180–2184
  26. Falcon C, Pfliegler G, Deckmyn H, et al. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochemical and Biophysical Research Communications. 1988;157:1190–1196
  27. Ferreira IA, Mocking AI, Feijge MA, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:417–422
  28. Ferreira IA, Eybrechts KL, Mocking AI, et al. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. The Journal of Biological Chemistry. 2004;279:3254–3264
  29. Ha H, Lee HB. Oxidative stress in diabetic nephropathy: basic and clinical information. Current Diabetes Reports. 2001;1:282–287
  30. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:2309–2315
  31. Davi G, Falco A, Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chemistry and Physics of Lipids. 2004;128:149–163
  32. Pratico D, Smyth EM, Violi F, et al. Local amplification of platelet function by 8-iso-PGF2a is not mediated by thromboxane receptor isoforms. The Journal of Biological Chemistry. 1996;271:14916–14924
  33. Minuz P, Andrioli G, Degan M, et al. The F2-isoprostane 8-epi prostaglandin F2a increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. Arteriosclerosis, Thrombosis, and Vascular Biology. 1998;18:1248–1256
  34. Ross R. Atherosclerosis – an inflammatory disease. The New England Journal of Medicine. 1999;340:115–126
  35. De Vriese AS, Verbeuren TJ, Van de Voorde J, et al. Endothelial dysfunction in diabetes. British Journal of Pharmacology. 2000;130:963–974
  36. Kario K, Matsuo T, Kobayashi H, et al. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:1114–1120
  37. De Cristofaro R, Rocca B, Vitacolonna E, et al. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. Journal of Thrombosis and Haemostasis. 2003;1:250–256
  38. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. The New England Journal of Medicine. 2005;353:2373–2383
  39. American Diabetes Association . Aspirin therapy in diabetes (Position Statement). Diabetes Care. 2004;27(Suppl. 1):S72–S73
  40. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases (AHA Scientific Statement). Circulation. 2002;106:388–391
  41. Rydén L, Standl E, Bartnik M, et al., Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) , European Association for the Study of Diabetes (EASD)  Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal. 2007;28:88–136
  42. Steering Committee of the Physicians' Health Study Research Group . Final report on the aspirin component of the ongoing Physicians' Health Study. The New England Journal of Medicine. 1989;321:129–135
  43. ETDRS Investigators . Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA. 1992;268:1292–1300
  44. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762
  45. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet. 2001;357:89–95
  46. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ (Clinical Research Ed.). 1994;308:81–106
  47. Bertrand ME, Rupprecht HJ, Urban P, et al., CLASSICS Investigators  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000;102:624–629
  48. CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339
  49. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. The American Journal of Cardiology. 2002;90:625–628
  50. Yusuf S, Zhao F, Mehta SR, et al., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England Journal of Medicine. 2001;345:494–502
  51. Angiolillo DJ, Shoemaker SB, Desai B, et al. A randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the OPTIMUS (Optimizing anti-Platelet Therapy In diabetes MellitUS) study. Circulation. 2007;115:708–716
  52. Peters RJ, Mehta SR, Fox KA, et al., Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators  Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682–1687
  53. Anderson JL, Adams CD, Antman EM, American College of Cardiology , American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) , American College of Emergency Physicians , et al ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non–ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal of the American College of Cardiology. 2007;50:e1–157
  54. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117:296–329
  55. Sabatine MS, Cannon CP, Gibson CM, et al., CLARITY-TIMI 28 Investigators  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. The New England Journal of Medicine. 2005;352:1179–1189
  56. Sabatine MS, Cannon CP, Gibson CM, et al., Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators , Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators  Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294:1224–1232
  57. Chen ZM, Jiang LX, Chen YP, et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet. 2005;366:1607–1621
  58. Bhatt DL, Fox KA, Hacke W, et al., CHARISMA Investigators , Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Investigators  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The New England Journal of Medicine. 2006;354:1706–1717
  59. Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. Journal of Thrombosis and Haemostasis. 2005;3:1309–1311
  60. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. Journal of the American College of Cardiology. 2007;49:1505–1516
  61. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot study including 189 post-stroke patients. Thrombosis Research. 1993;71:397–403
  62. Mueller MR, Salat A, Stangle P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thrombosis and Haemostasis. 1997;78:1003–1007
  63. Grundmann K, Jaschonek K, Kleine B, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. Journal of Neurology. 2003;250:63–66
  64. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–1655
  65. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. Journal of the American College of Cardiology. 2003;41:961–965
  66. Gengo FM, Rainka M, Robson M, et al. Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. Journal of Clinical Pharmacology. 2008;48:335–343
  67. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. Journal of the American College of Cardiology. 2005;46:1705–1709
  68. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007;115:3156–3164
  69. Frelinger AL, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006;113:2888–2896
  70. Gengo FM, Rubin L, Robson M, et al. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. Journal of Clinical Pharmacology. 2008;48:117–122
  71. DiChiara J, Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007;56:3014–3019
  72. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Archives of Internal Medicine. 2007;167:1593–1599
  73. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ (Clinical Research Ed.). 2008;336:195–198
  74. DiMinno G, Silver MJ, Cerbone AM, et al. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood. 1986;68:886–891
  75. Mehta SS, Silver RJ, Aaronson A, et al. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. The American Journal of Cardiology. 2006;97:567–570
  76. Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) – its relation to metabolic control. Thrombosis Research. 2004;113:101–113
  77. Takahashi S, Ushida M, Komine R, et al. Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thrombosis Research. 2007;119:517–524
  78. Neri Serneri GG, Coccheri S, Marubini E, et al., Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group  Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. European Heart Journal. 2004;25:1845–1852
  79. Geisler T, Anders N, Paterok M, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care. 2007;30:372–374
  80. Serebruany V, Pokov I, Kuliczkowski W, et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thrombosis and Haemostasis. 2008;100:76–82
  81. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–2130
  82. Urban P, Gershlick AH, Guagliumi G, et al., e-Cypher Investigators  Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation. 2006;113:1434–1441
  83. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113:1108–1113
  84. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667–678
  85. Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: benefits and limitations. American Heart Journal. 2008;156(2 Suppl):S3–S9
  86. Smith SC, Feldman TE, Hirshfeld JW, et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines , ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention–summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention). Catheterization and Cardiovascular Interventions. 2006;67:87–112
  87. Angiolillo DJ, Capranzano P, Goto S, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. European Heart Journal. 2008;29:2202–2211
  88. Douglas JS, Holmes DR, Kereiakes DJ, et al., Cilostazol for Restenosis Trial (CREST) Investigators  Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112:2826–2832
  89. Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). Journal of the American College of Cardiology. 2008;51:1181–1187
  90. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001;104:2767–2771
  91. Angiolillo DJ. ADP receptor antagonism: what's in the pipeline?. American Journal of Cardiovascular Drugs. 2007;7:423–432
  92. Angiolillo DJ, Bates ER, Bass TA. Clinical profile of prasugrel, a novel thienopyridine. American Heart Journal. 2008;156(2 Suppl):S16–S22
  93. Wiviott SD, Braunwald E, McCabe CH, et al., TRITON-TIMI 38 Investigators  Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine. 2007;357:2001–2015
  94. Wiviott SD, Braunwald E, Angiolillo DJ, et al., TRITON-TIMI 38 Investigators  Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118:1626–1636
  95. Angiolillo DJ, Guzman LA. Clinical overview of promising nonthienopyridine antiplatelet agents. American Heart Journal. 2008;156(2 Suppl):S23–S28

PII: S1521-690X(08)00170-X

doi: 10.1016/j.beem.2008.12.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 3 , Pages 375-388 , June 2009

Article Tools

* Image Usage & Resolution